The long-term objective is to eradicate or arrest the growth of large established solid tumors by adoptively transferred T cells and to prevent the outgrowth of disseminated cancer. Eradication depends on T cells (i) eliminating the majority of cancer cells by direct antigen-specific (perforin-dependent) killing and (ii) destroying non-malignant tumor stroma cross-presenting antigens released from the cancer. The latter is needed to eliminate cancer cell variants responsible for recurrences. Radiation or chemotherapy causes a transient increase in stromal loading with tumor antigen and therefore synergizes with the therapeutic effect of T cells. Tumor eradication is obviously preferable to tumor arrest. However, for many aggressively growing rapidly lethal cancers that may have down-regulated MHC expression, long-term arrest of growth with equilibrium between the host and cancer would be an acceptable goal. This has been achieved in an experimental setting where T cells can only target and destroy stroma loaded with antigen released from cancer cells into the tumor microenvironment, but there are many unanswered questions. Thus, Aim 1 is to determine the mechanisms and the robustness of equilibrium induced by T cells targeting stroma only.
Aim 2 determines the levels of mutant-self or normal self antigens needed to be expressed by the cancer cells to sensitize stroma for destruction and whether T cells with high-affinity TCRs can destroy stroma expressing lower levels of cross- presented target antigen without penalty of autoimmune destruction.
Aim 3 will determine whether the principle of equilibrium by stromal destruction can be extended to micrometastatic or metastatic cancers including human cancers, such as ovarian and breast cancer growing in mice. Can micro-disseminated cancer cells or metastases be arrested, and do arrested cancers cease to disseminate cancer cells into the periphery? Optical imaging of established large tumors through a skin-fold window will be used to observe the in vivo effects of adoptively transferred T cells observed in real-time sequence with spatial definition. Understanding the reasons for the powerful equilibrium that can be exerted by targeting only stroma could suggest new strategies for more effective adoptive T cells therapy.

Public Health Relevance

The proposed research examines the novel concept of permanently arresting tumor growth by targeting cancers indirectly with T cells killing stromal cells that present peptides derived from cancer-specific proteins, which are released from the cancer cells, on their MHC. By targeting and killing the stromal cells, multiple factors released by stroma, which promote and are needed for tumor growth, are eliminated. Thus, continuous destruction of stromal cells cross-presenting specific peptide/MHC complexes derived from cancer-specific proteins can cause long-term arrest of cancers including aggressively growing cancers that have become highly resistant to direct killing by T cells or other therapies.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Transplantation, Tolerance, and Tumor Immunology (TTT)
Program Officer
Mccarthy, Susan A
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Chicago
Schools of Medicine
United States
Zip Code
Arina, Ainhoa; Schreiber, Karin; Binder, David C et al. (2014) Adoptively transferred immune T cells eradicate established tumors despite cancer-induced immune suppression. J Immunol 192:1286-93
Binder, David C; Schreiber, Hans (2014) Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors--letter. Cancer Res 74:632; discussion 635
Liu, Rebecca Berlant; Engels, Boris; Schreiber, Karin et al. (2013) IL-15 in tumor microenvironment causes rejection of large established tumors by T cells in a noncognate T cell receptor-dependent manner. Proc Natl Acad Sci U S A 110:8158-63
Engels, Boris; Engelhard, Victor H; Sidney, John et al. (2013) Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinity. Cancer Cell 23:516-26
Engels, Boris; Chervin, Adam S; Sant, Andrea J et al. (2012) Long-term persistence of CD4(+) but rapid disappearance of CD8(+) T cells expressing an MHC class I-restricted TCR of nanomolar affinity. Mol Ther 20:652-60
Engels, Boris; Rowley, Donald A; Schreiber, Hans (2012) Targeting stroma to treat cancers. Semin Cancer Biol 22:41-9
Liu, Rebecca B; Engels, Boris; Arina, Ainhoa et al. (2012) Densely granulated murine NK cells eradicate large solid tumors. Cancer Res 72:1964-74
Schreiber, Karin; Arina, Ainhoa; Engels, Boris et al. (2012) Spleen cells from young but not old immunized mice eradicate large established cancers. Clin Cancer Res 18:2526-33
Philip, Mary; Schietinger, Andrea; Schreiber, Hans (2010) Ribosomal versus non-ribosomal cellular antigens: factors determining efficiency of indirect presentation to CD4+ T cells. Immunology 130:494-503
Schietinger, Andrea; Philip, Mary; Liu, Rebecca B et al. (2010) Bystander killing of cancer requires the cooperation of CD4(+) and CD8(+) T cells during the effector phase. J Exp Med 207:2469-77

Showing the most recent 10 out of 66 publications